Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT06625775
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-10-29Est. Completion: 2028-11
Enrollment target: 392 participants Locations- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- University of California San Diego Moores Cancer Center, San Diego, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
- St. Lukes Hospital of Kansas City, Kansas City, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- SCRI Oncology Partners, Nashville, Tennessee, United States
- SCRI at Mary Crowley, Dallas, Texas, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Other microbiome trials you might be interested in
Advanced CancerMetastatic CancerSolid TumorMelanomaNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Anaplastic Thyroid Cancer (ATC)
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with ad…
Los Angeles, United StatesEst. completion Apr 1, 2028
The University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesUniversity of Texas San Antonio (UTSA), San Antonio, Texas, United StatesFred Hutchinson Cancer Center, Seattle, Washington, United StatesWisconsin Institute for Medical Research, Madison, Wisconsin, United StatesScientia Clinical Research, Randwick, New South Wales, AustraliaPeter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaLiga Contra o Câncer, Natal, Rio Grande do Norte, BrazilFUTTURA Oncologia, Porto Alegre, Rio Grande do Sul, BrazilHospital São Lucas da PUCRS, Porto Alegre, Rio Grande do Sul, BrazilInstituto do Câncer do Estado de São Paulo - ICESP, São Paulo, São Paulo, BrazilClinica de Pesquisas e Centro de Estudos Em Oncologia Ginecologica e Mamaria Ltda, São Paulo, São Paulo, BrazilIEPE - Unimed Sorocaba, Sorocaba, São Paulo, BrazilInstitut régional du Cancer de Montpellier - Val d'Aurelle, Montpellier, Occitanie, FranceInstitut Curie - René-Huguenin Hospital, Saint-Cloud, Paris, Francelnstitut de Cancérologie de l'Ouest - Site Saint-Herblain, Saint-Herblain, Pays de la Loire Region, FranceInstitut Bergonie, Bordeaux, FranceCentre Léon Bérard, Lyon, FranceInstitut Gustave Roussy, Villejuif, Île-de-France Region, FranceAsan Medical Center (AMC), Seoul, Seoul, South KoreaSeoul National University Hospital, Seoul, South KoreaHospital Universitario Vall d'Hebron, Barcelona, Catalonia, SpainHospital Beata Maria Ana, Madrid, Madrid, SpainHospital Quiron Madrid - NEXT Oncology, Pozuelo de Alarcón, Madrid, SpainIOB Institute of Oncology - Hospital Quironsalud Barcelona, Barcelona, SpainSTART Barcelona - HM Nou Delfos Hospital, Barcelona, SpainHospital Universitari Arnau de Vilanova, Lleida, SpainHospital Universitario Fundación Jiménez Díaz, Madrid, SpainHospital Universitario 12 de Octubre, Madrid, SpainHospital Universitari i Politècnic La Fe, Valencia, SpainSoft Tissue Sarcoma (STS)
Breast Neoplasms
This phase 1b/2a study evaluates AL58805, an oral investigational drug that blocks PI3K and mTOR signaling, in combinati…
Houston, United StatesEst. completion Sep 1, 2030
Very Rare TumorsVery Rare CancersOther Solid TumorsSolid TumorPediatric Rare Tumors
Background:
All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewe…
Bethesda, United StatesEst. completion Apr 1, 2035